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A transformation-defective mutant of Abelson murine leukemia
virus lacks protein kinase activity
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ABSTRACT A transformation-defective mutant of Abelson
murine leukemia virus (A-MuLV), called A-MuLV-P92td, has
been isolated. The mutant encodes a serologically identifiable
A-MuLV protein of molecular weight 92,000 (P92) but it lacks
the ability to transform either fibroblasts or bone marrow
lymphoid cells. In contrast to the protein made by transforming
strains of A-MuLV, the protein made by A-MuLV-P92td does
not become phosphorylated during in vitro incubation with[y-32PJATP. If the protein is mixed with proteins from cells
transformed by a functional A-MuLV strain, phosphorylation
of P92 occurs, showing that its ability to accept phosphate is not
altered by the mutation. These parallel changes provide genetic
evidence that the A-MuLV protein is a transforming protein and
that its associated protein kinase activity (EC 2.7.1.37) is a cru-
cial part of its transforming ability.
Abelson murine leukemia virus (A-MuLV) is a member of the
replication-defective rapidly transforming group of retroviruses
(1-3). It was derived during passage in mice of the replica-
tion-competent Moloney murine leukemia virus (M-MuLV)
and can rapidly induce leukemia in dvo as well as transform
bone marrow cells and some established mouse cell lines in vitro
(4-7). Many A-MuLV-transformed lymphoid cells have char-
acteristics of pre-B-lymphocytes (8, 9).
The single-stranded RNA genome of the prototype A-MuLV
strain is 5.6 kilobases (kb) in length (10). It is composed of 1320
bases at its 5' end and 730 bases at its 3' end derived from the
parental M-MuLV strain and a 3600-base central region derived
from unique sequences in normal mouse DNA (refs. 10 and 11;
unpublished results). A number of A-MuLV strains have been
identified (12); each encodes a protein corresponding to a fusion
between the amino-terminal region of the M-MuLV gag gene
product and a polypeptide encoded by the mouse cell-derived
sequences (12-14). These proteins have molecular weights
ranging from 160,000 to 90,000. The prototype A-MuLV strain
encodes a 120,000 molecular weight protein called P120. We
use the notation A-MuLV-P120 to denote this strain. P120 is a
phosphorylated nonglycosylated protein, of which a portion
is exposed on the exterior of the plasma cell membrane of in-
fected cells (15).
When P120 or the other A-MuLV proteins are incubated in
vitro with [y-32P]ATP, radioactive phosphate is transferred to
one or more tyrosine residues in the protein (16). This behavior
is similar to the protein kinase activities (EC 2.7.1.37) associated
with the Rous sarcoma virus src gene product and the middle
T (tumor) antigen of polyoma virus (17-19). Because of the
close association of tyrosine-phosphorylating activity with
transforming proteins and also because the A-MuLV fusion
proteins are the only known gene products of the A-MuLV
genome (11), we have assumed that these proteins are respon-
sible for transformation by the various A-MuLV strains. No
direct genetic or biochemical data have yet appeared to support
this assumption.
The identification of the transforming gene of Rous sarcoma
virus, src, and its gene product, pp60src, was greatly aided by
the isolation of transformation-defective (td) mutants (20).
Because Rous sarcoma virus contains genes for replicative
functions, assays that detected expression of replication genes
in the absence of transformation could be used to identify such
mutants. In the case of A-MuLV (and other defective trans-
forming retroviruses) there are no linked functional replication
genes that can be used in the section of td mutants. As an al-
ternative one can search for cells that express A-MuLV antigens
but are not transformed (21). By such screening procedures, we
have isolated a spontaneous td mutant of A-MuLV. It encodes
an antigenically recognizable A-MuLV protein, but the protein
lacks the associated protein kinase activity found in proteins
from transforming strains of A-MuLV. The coincident loss of
kinase activity and transforming potential lends strong support
to the hypothesis that the A-MuLV protein is a transforming
gene product that may function as a protein kinase.
MATERIALS AND METHODS
Cell Lines and Viruses. The cell lines used and their deri-
vations were: ANN-1 (A-MuLV-P120-transformed nonpro-
ducer NIH/3T3 mouse fibroblast); A2 (A-MuLV-P120-trans-
formed nonproducer NIH/3T3 fibroblast that has changed to
producing P90 and P92); 2M3 (A-MuLV-P120-transformed
nonproducer lymphoid cell from BALB/c bone marrow); and
NIH/3T3 uninfected fibroblasts. Cell lines superinfected with
M-MuLV are designated as /M (as in 2M3/M). All cells were
cultured as described (22, 23). Assays for helper virus plaque-
forming units (24), A-MuLV focus-forming units in fibroblasts
(5), and A-MuLV lymphoid cell transformation (22, 23) were
as described.
Cell Morphology. Cells were seeded (1 X 105 per ml) on
sterile glass microscope slide chambers (Lab-Tek Products,
Naperville, IL) and allowed to grow for 2 days prior to washing
and fixation with 10% (wt/vol) formalin. Wet mounts were
photographed at X250, using the phase-contrast optics on a
Leitz microscope, with Tri-X film (Kodak).
Cell Labeling and Immunoprecipitation. Techniques for
[s5S]methionine and [3H]leucine metabolic labeling of cells and
extraction, and details of immunoprecipitation, antisera, and
electrophoretic analysis have been published (13, 15, 25-27).
In Vitro Kinase Activity. Immunoprecipitates of A-MuLV
proteins were tested for kinase activity in a Mn2+-activated
assay as described (16).
Abbreviations: A-MuLV, Abelson murine leukemia virus; M-MuLV,
Moloney murine leukemia virus; kb, kilobase(s); td, transformation-
defective.
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RESULTS
Isolation of an A-MuLV td Mutant. The A-MuLV td mu-
tants arose during the study of a particular A-MuLV stock. The
stock was prepared from the A2 cell line, an A-MuLV-P120-
transformed nonproducer line derived by A. Shields after single
cell-single virus infection of NIH/3T3 cells with a stock of
A-MuLV from ANN-1/M cells (10). Originally, the A2 cell line
expressed the A-MuLV P120 protein as its only MuLV-related
product, but on continued passage over 2 years smaller sero-
logically related polypeptides appeared in the cells and ulti-
mately P120 became undetectable. The major A-MuLV-related
polypeptide in the cells became one of 90,000-92,000 molecular
weight.
A stock of A-MuLV was prepared by superinfection of these
late-passage A2 cells with M-MuLV to give the A2/M cell line.
NIH/3T3 cells were then infected with the A2/M stock at a
multiplicity of infection of about 0.5 focus-forming units per
cell and distributed at about 0.3 cell per microwell. Clones were
screened morphologically and both transformed and non-
transformed clones were selected and tested for synthesis of
A-MuLV and M-MuLV proteins by metabolic labeling and
immunoprecipitation. Of 20 transformed clones, all expressed
a 90,000-92,000 molecular weight A-MuLV protein. Of 18
nontransformed clones, two expressed a 92,000 molecular
weight protein. One of these untransformed clones, called Fl-3,
which had no evidence of M-MuLV expression, was selected
for further study. One nonproducer transformed clone, called
Tx-15, was also selected. (Fl refers to the flat morphology of the
cells, Tx to transformed morphology.) For reference, these
cell lines and viruses derived from them are described in
Table 1.
Growth Properties of Fl3 and Tx-15 Clones. When grown
as monolayers, Fl-S cells remained tightly adherent to the
substratum and nonrefractile, even on prolonged growth and
refeeding (Fig. 1 Left). The final cell density of F1-3 cells was
somewhat (15-20%) higher than that of NIH/3T3 cells. Tx-15
cells (Fig. 1 Right) showed the highly refractile and loosely
adherent phenotype seen for NIH/3T3 cells transformed by
other A-MuLV strains (5). When Tx-15 cells were seeded as
single cells in soft agar (200 per 10-cm plate), over 75% grew
into macroscopic colonies (1- to 3-mm diameter) within 2-2.5
weeks. F1-3 cells plated under identical conditions showed no
macroscopic colonies after 3 weeks. If the plates were refed
weekly, however, and the incubation was continued for 5-6
weeks, small colonies (0.5- to 1-mm diameter) representing
about 10% of the initially seeded cells were visible. Uninfected
NIH/3T3 cells showed no colonies under such conditions. Four
of these Fl-3-derived colonies were picked, and when grown
on tissue culture plastic dishes they showed the same growth
Table 1. Nomenclature of cells and viruses
Designation Properties
Cells
Fl-3 Nontransformed NIH/3T3 cells
containing the defective
A-MuLV-P92td provirus
Tx-15 Transformed NIH/3T3 cells containing
both the defective A-MuLV-P92td
provirus and a transforming
A-MuLV-P90 provirus
FI-3/M Fl-3 cells superinfected with M-MuLV
Viruses
A-MuLV-P90 An A-MuLV strain that makes a
protein of molecular weight 90,000
A-MuLV-P92td A td strain of A-MuLV that makes
a protein of molecular weight 92,000
I,
'K
FIG. 1. Cultures of Fl-3 (Left) and Tx-15 (Right) cells examined
by phase-contrast microscopy. (X300.)
properties as the parent Fl-3 cells. These microcolonies may
result from some residual expression of the A-MuLV trans-
forming function.
Serological Comparison of A-MuLV Protein from Tx-15
and F1-3.Celis. To examine the A-MuLV-related proteins made
by Tx-15 and Fl-S cells, the cells were labeled with [35S]me-
thionine, and immunoprecipitated products were analyzed by
NaDodSO4/polyacrylamide gel electrophoresis. When a mouse
antiserum known to react with the A-MuLV-specific region of
the A-MuLV protein (15) was used for immunoprecipitation
in the presence of an excess of unlabeled M-MuLV proteins, a
90,000-92,000 molecular weight protein was found in both lines
(Fig. 2, lanes B). Normal mouse serum did not precipitate this
protein (lanes A). A polyvalent goat anti-M-MuLV serum also
precipitated the 90,000-92,000 molecular weight proteins (lanes
C) but revealed no helper virus proteins. Sometimes, the
90,000-92,000 molecular weight region from Tx-15 cells was
resolved into two separate components, called P90 and P92, but
the Fl-3 protein appeared to be a single P92 band.
When these studies were performed, the significance of the
P90 and P92 proteins was not apparent. In recent work (un-
published) it has become evident that Fl-3 cells have one A-
MuLV provirus but TX-15 cells have two proviruses. The Fl-3
provirus produces RNA 4.9 kb in length and encodes the P92;
the two Tx-15 proviruses make 4.9-kb and 5.6-kb RNAs en-
coding, respectively, P92 and P90. P90 synthesis is apparently
a consequence of a termination mutation in an A-MuLV ge-
nome that originally encoded a P120; the P90 is still functional
as a transforming protein. P92 synthesis by the 4.9-kb genome
is a consequence of a deletion mutation in the A-MuLV-specific
region of the A-MuLV genome and this protein is apparently
transformation deficient.
Henceforth, the A-MuLV strain in the Fl-3 cells will be re-
ferred to as A-MuLV-P92td.
P92 Lacks A-MuLV Kinase Activity. We have previously
demonstrated that the A-MuLV protein is associated with a
protein kinase activity that transfers the y phosphate of ATP
to a tyrosine residue(s) in the A-MuLV protein (16). This re-
action appeared to be carried out by the A-MuLV protein itself,
but we have not been able to formally rule out the participation
of host cell kinase. A functional role for this kinase activity in
A-MuLV transformation has not been demonstrated.
To examine the protein kinase activity of the A-MuLV-re-
lated P90 and P92 proteins from Fl-3 and Tx-15 cells, the cells
were labeled with [3H]leucine and the A-MuLV proteins were
immunoprecipitated. Approximately equal amounts of [3H]-
leucine-labeled 90,000-92,000 molecular weight protein
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FIG. 2. Serological comparison of P92 and P90 proteins. Cells (2
X 106) labeled with 50 ACi of [3%S]methionine (New England Nuclear;
1 Ci = 3.7 X 1010 becquerels) for 1 hr were extracted, clarified, im-
munoprecipitated with Staphylococcus aureus, and analyzed by
NaDodSOJ10% polyacrylamide gel electrophoresis as described (13,
15, 25, 26). Gel 1 is F1-3 cells; gel 2 is Tx-15 cells. Lanes A, normal
mouse serum. Lanes B, anti-Abelson tumor serum (15) in the presence
of unlabeled M-MuLV virion proteins at 100 ug/ml. Lanes C, goat
anti-M-MuLV serum.
(monitored by fluorography) were recovered from equal
numbers of Fl-S or Tx-15 cells (Fig. 3, lanes A and B). Somewhat
smaller apparent breakdown products of P90 and P92 were also
present, as seen previously for most A-MuLV proteins (13).
When identical immunoprecipitates were assayed for kinase
activity by using [1-32P]ATP as a substrate and direct autora-
diography to monitor `32P incorporation, P92 from Fl-S cells
showed no detectable incorporation above background even
on prolonged exposures, whereas the mixture of P90 and P92
from Tx-15 cells was labeled to the same extent as proteins of
other transforming strains of A-MuLV (Fig. 3, lanes C and
D).
One possible explanation for the lack of 32P incorporation
in immunoprecipitates containing P92 alone could be that the
protein suffered a mutation that altered the phosphate acceptor
site. Previously we had shown that heat-inactivated A-MuLV
protein that was unable to label itself could be labeled if mixed
and coimmunoprecipitated with an active A-MuLV protein of
a distinguishable strain (28). This coprecipitation assay was used
to examine the phosphate acceptor site in the P92 protein.
Clarified extracts (106 cells per ml) were prepared from Fl-3,
Tx-15, and an A-MuLV-P160-infected NIH/3T3 cell line.
Portions were heat inactivated, A-MuLV proteins were im-
munoprecipitated from a single lysate or from mixtures, and
the precipitates were allowed to react under standard kinase
conditions with [,y-32P]ATP and then were analyzed by Na-
DodSO4/polyacrylamide gel electrophoresis. As expected,
neither P92 (Fig. 3, lane E) nor heat-treated P92 (lane F) was
phosphorylated. If heat-treated Fl-S extract was mixed with
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FIG. 3. Labeling of P92 and P90 proteins by incubation of im-
munoprecipitates with [y-32P]ATP. Extracts of [3H]leucine-labeled
cells (100 ,Ci per 106 cells for 1 hr at 370C) or unlabeled cells were
used alone or in mixtures for kinase reactions as outlined below for
measurement of cooperative kinase activity. 411 kinase reactions were
carried out on S. aureus-bound immunoprecipitates, formed using
goat anti-MuLV serum, in 50 ,l of 20 mM Tris.HCl, pH 8.0/10mM
MnCl2 containing 1 UCi of ['y-32P]ATP (2300 Ci/mmol, New England
Nuclear) at 300C for 10 min. Proteins were eluted into NaDodSO4-
containing electrophoresis sample buffer and submitted to electro-
phoresis through NaDodSO4/10% polyacrylamide gels and developed
by fluorography or autoradiography as described (13, 15, 25, 26).
Lanes A and B, [3H]leucine-labeled immunoprecipitates, developed
by fluorography, from Fl-3 and Tx-15 cells, respectively. Lanes C and
D, kinase reaction products of immunoprecipitated lysates of Fl-3 and
Tx-15 cells, respectively, developed by direct autoradiography. The
same extracts shown in lanes A and B were used for these reactions.
Lanes E-K, kinase activity monitored by autoradiography for: (E)
P92 immunoprecipitated from Fl-3 cells; (F) Fl-3 extract heated at
680C for 1 min prior to immunoprecipitation of P92; (G) heated Fl-3
extract mixed with A-MuLV-P160-infected NIH/3T3 cell extract
prior to immunoprecipitation; (H) P90/P92 mixture immunopre-
cipitated from Tx-15 cells; (I) Tx-15 extract heat-inactivated before
immunoprecipitation of P90-P92; (J) heated Tx-15 extract mixed
with A-MuLV-P160-infected NIH/3T3 cell extract prior to immu-
noprecipitation; (K) A-MuLV-P160-infected NIH/3T3 cell extract
immunoprecipitated alone.
the P160-containing extract (lane G), then both P160 and P92
were labeled. Thus P92 has a phosphate acceptor site as mea-
sured in this coprecipitation assay. A similar set of reactions
using Tx-15 extract showed that, in unheated preparations, P90
was labeled with phosphate (lane H), that the activity could be
heat-inactivated (lane I), and that heat-inactivated P90 could
be labeled when mixed with a p160-containing extract (lane
J). The extract with P160 alone labeled only the 160,000 mo-
lecular weight protein (lane K). In other experiments (data not
shown) P92 was unable to phosphorylate another heat-inacti-
vated A-MuLV protein such as P160 in similar coprecipitation
kinase tests.
The Defective Transfonnation Phenotype of Fl-S Cells Is
a Viral Not a Cellular Defect. To examine whether the lack
of transformed phenotype and kinase activity in Fl-3 cells was
due to an abnormal cellular rather than viral function, F1-3 cells
and NIH/3T3 cells were infected with wild-type A-MuLV
stocks. After 2 hr of exposure to the virus, the cells were re-
moved from the dish with trypsin and suspended in agar at 500
Microbiology: Witte et al.
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cells per 10-cm plate. Macroscopic agar colonies were counted
after 2 weeks. Not only could the Fl-3 cells be transformed by
superinfection with a second A-MuLV strain, but the number
of agar colonies was 3-5 times greater than on control NIH/3Th
cells. In addition, the average size of the colonies of superin-
fected Fl-3 cells was 2-3 times that of infected NIH/3T3 cells.
This enhancement was found for wild-type A-MuLV stocks that
make P90, P120, and P160 proteins. The precise mechanism
for this increased number of agar colonies is unclear, but the
A-MuLV genome in Fl-S cells might provide a complementary
function to other A-MuLV strains.
To determine if an altered viral genome was responsible for
the transformation-defective phenotype of Fl-3 cells, we in-
fected Fl-S3 Tx-15, and 2M3-a control A-MuLV-P120-trans-
formed cell line-with M-MuLV and assayed the rescued A-
MuLV genomes for fibroblast and lymphoid cell transforming
capability (Table 2). The virus from Fl-S cells showed no ability
to transform either fibroblast or lymphoid cells. All three virus
stocks, however, showed high levels of helper virus, indicating
no block to retrovirus multiplication in Fl-S cells. The A-MuLV
stocks from Tx-15 and 2M3 cells showed normal levels of fi-
broblast transformation but the Tx-15 virus, although able to
transform lymphoid cells, was much less efficient in this assay
than the 2M3-derived virus. Reduced lymphoid cell trans-
forming ability by another A-MuLV-P90 strain has been ob-
served (unpublished data).
The lack of transformation by the virus stock rescued from
Fl-S cells could be a consequence of either an inability to rescue
any A-MuLV genome from F1-S cells or an intrinsic transfor-
mation defect in a rescued A-MuLV genome from the cells. To
determine if an A-MuLV-P92td genome was rescued from Fl-S
cells and passed to NIH/3T3 cells, we assayed for the presence
of the 92,000 molecular weight A-MuLV-specific protein in
cells infected by the virus stock rescued from Fl-3 cells. When
NIH/3T3 cells were mass infected with an undiluted Fl-3/M
stock and allowed to grow for 4 days, no alteration of growth
morphology was evident compared to uninfected NIH/3T3
cells. Two days later the cells were labeled for 1 hr with [M5SI-
methionine, extracted, and clarified for immunoprecipitation.
As expected, the cells contained all three of the major helper
M-MuLV precursor proteins (29): Pr65gag, Pr8Oent, and
Prl80gag-Pol (Fig. 4, lanes C-F). In addition, they contained
a 92,000 molecular weight band that contained both A-
MuLV-specific determinants-monitored by precipitation with
anti-Abelson tumor serum (15) (Fig. 4, lane B)-and gag gene
determinants (lanes C, E, and F). Thus, in the absence of pas-
sage of any transforming ability, we could demonstrate the
Table 2. Biological properties of A-MuLV strains
Fibroblast- Liquid culture bone
transforming marrow lymphoid
Virus Helper titer, activity, transformation
stock* PFU/mlt FFU/mlt assay for A-MuLV§
Fl-3/M l X 107 0 0/10
Tx-15/M 5 X 106 1 X 106 6/10w
2M3/M 5 X 105 1.2 X 105 9/911
* Stocks prepared by superinfection of Fl -3, Tx-15, and 2M3
(PI-20-containing, A-MuLV-transformed, nonproducer) cells with
M-MuLV. Filtered 18-hr collections were used.
t Helper virus titers, expressed as plaque-forming units/ml, were
measured by S+L- assay (24).
Fibroblast focus units were measured on NIH/3T3 cells (5).
§ Mass infection of BALB/c bone marrow in liquid cultures as de-
scribed (6, 22). Numbers are transformed cultures per cultures as-
sayed.
Transformation noted on day 15.
Transformation noted on day 9.
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FIG. 4. Transfer of P92 expression by infection. NIH/3T3 cells
were mass infected with a stock ofA-MuLV from F1-3/M cells. After
6 days, 5 X 106 cells were labeled with [35S]methionine (200 ,Ci) for
1 hr at 37°C and then extracted, and portions were immunoprecipi-
tated with: Lane A, normal mouse serum; lane B, mouse anti-Abelson
tumor serum in the presence of unlabeled M-MuLV proteins at 100
,ug/ml; lane C, rabbit anti-p15/reverse transcriptase; lane D, rabbit
anti-gp70; lane E, rabbit anti-p30; lane F, goat anti-M-MuLV virions.
Samples were analyzed on a NaDodSO4/10% polyacrylamide gel de-
veloped by fluorography. Lanes A and B are from a 3-day exposure;
lanes C-F are from a 1-day exposure.
passage of the A-MuLV-specific gene product of the A-
MuLV-P92td strain. Analysis of extracts of this mass-infected
population for A-MuLV kinase activity was negative (data not
shown). The A-MuLV-P92td genome is thus rescuable but in-
trinsically defective.
DISCUSSION
By screening nontransformed cells in a population infected with
A-MuLV, we have identified a cell line that makes an A-
MuLV-related protein but is not transformed. This line contains
a virus called A-MuLV-P92td, which can be rescued by su-
perinfection and passed to fresh cells without causing trans-
formation; thus, the virus is truly transformation-defective.
Because cells infected with A-MuLV-P92td can form micro-
colonies in agar after long periods of incubation, the virus may
retain a modicum of transforming ability, but by most char-
acteristics it has lost its transforming ability for both fibroblasts
and lymphoid cells.
We were able to isolate A-MuLV-P92td because it still ex-
pressed a protein with both gag and A-MuLV-specific deter-
minants. The mutation that gave rise to A-MuLV-P92td inac-
tivated both its kinase activity and its transforming ability. In
the absence of a total genetic analysis of the A-MuLV-P92td
genome, we cannot be certain that it has only a single defect,
but, by preliminary restriction enzyme analysis of its DNA
provirus, it appears to have suffered a single 700-base deletion
of the A-MuLV-P120 genome in the A-MuLV-specific region
of the genome. On the assumption that this deletion is the only
alteration in A-MuLV-P92td compared to A-MuLV-P120, the
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concomitant loss of kinase activity and transforming activity
clearly associates these two parameters. Significantly, the P92
protein can still serve as a substrate for the kinase found in A-
MuLV-transformed cellk Thus the mutation in A-MuLV-P92td
has separated the kinase activity associated with the A-MuLV
protein from the ability of the protein to act as a substrate for
phosphorylation. One interpretation of this dissociation of
functions is that separate regions of A-MuLV-transforming
proteins are involved in kinase and substrate activity and that
at least the kinase activity is required for transformation. We
cannot rule out, however, that the A-MuLV protein induces a
cellular kinase and that the induction function is defective in
A-MuLV-P92td.
Similarities exist between the A-MuLV protein and the avian
sarcoma virus src gene product, although they have different
cellular targets for transformation. Both are found in cell
membrane fractions (15, 30) and both appear to catalyze pro-
tein kinase reactions that result in the formation of phos-
photyrosine (16, 19). src-containing viruses can transform fi-
broblasts but not hematopoietic cells. A-MuLV, by contrast,
transforms lymphoid cells as well as NIH/3T3 "fibroblasts,"
but it does not transform primary fibroblasts and its only ac-
tivity in animals is transformation of hematopoietic cells
(mainly lymphoid cells) (7). Proteins of other retroviruses and
DNA tumor viruses also have been associated with protein ki-
nase activity (18, 31-35). How these membrane-associated ki-
nase activities are related to the transforming ability of the vi-
ruses remains to be determined, but the commonality of
properties of these transforming proteins is remarkable.
The number of A-MuLV strains making different sizes of
protein is increasing and has required the development of the
somewhat cumbersome nomenclature used in this paper. There
is still at least one imprecision in the protein designation used
here. P90 from Fl-3 cells and Tx-15 cells is presumably the same
protein but we do not know if it is the same as a P90 previously
described (12). The new P90 should be designated P9OA unless
an exact correspondence to the previous P90 can be shown.
They may be identical, however, because both viruses making
these proteins arose from the A-MuLV-P120 strain, although
independently; both arose as a consequence of a small change
in the A-MuLV-P120 genome, presumably causing the ap-
pearance of a new termination codon (unpublished data); and
both are relatively deficient for lymphoid as opposed to fibro-
blast transformation (Table 2; unpublished data).
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